Hasil Pencarian  ::  Simpan CSV :: Kembali

"Dilaporkan terdapat 38,4 juta orang yang hidup dengan HIV pada tahun 2021 dan terdapat sebanyak 58 juta kasus kasus kronis Hepatitis C pada tahun 2019. Pengguna NAPZA suntik merupakan populasi yang paling rentan untuk terinfeksi kedua virus ini akibat jalur transmisi kedua virus ini yang sangat besar melalui jarum suntik tidak steril. Kedua penyakit ini dapat terjadi secara bersamaan yang menyebabkan percepatan progres keduanya menjadi kronis. Penelitian ini bertujuan untuk melihat faktor-faktor yang berhubungan dengan kejadian koinfeksi HIV/HCV untuk mencegah penyebaran yang lebih lanjut dengan melakukan analisis bivariat dengan menggunakan chi-square dan melihat crude prevalence ratio. Studi cross-sectional dari data STBP 2018-2019 di tujuh kabupaten/kota Jawa Barat populasi Penasun dilakukan dan didapatkan bahwa positivity rate koinfeksi HIV/HCV pada Penasun mencapai sebesar 9%. Ditemukan bahwa terdapat hubungan antara usia, jenis kelamin, tingkat pendidikan, status perkawninan, riwayat dipenjara, usia pertama kali menggunakan NAPZA suntik, lama menggunakan NAPZA suntik, pernah menggunakan alat suntik tidak steril, usia pertama kali berhubungan seksual, hubungan seksual satu tahun terakhir, penggunaan kondom dengan pasangan tetap, pengetahuan komprehensif HIV, akses LASS, dan akses PTRM dengan kejadian koinfeksi HIV/HCV. Dari hasil tersebut diperlukan intervensi yang tepat untuk mencegah dan menanggulangi tingginya kejadian koinfeksi HIV/HCV pada Penasun.

---

In 2021, approximately 38.4 million individuals were reported to be living with HIV, while an estimated 58 million cases of chronic hepatitis C were recorded in 2019. Among vulnerable populations, IDU (injecting drug users) face the highest risk of contracting both viruses due to the transmission through unsterile needles. Co-infection of HIV and HCV can occur simultaneously, leading to an accelerated progression of chronic infections. This research aims to identify factors associated with the occurrence of HIV/HCV co-infection in order to prevent further spread. Bivariate analysis using chi- square and examining the crude prevalence ratio was conducted using cross-sectional data from 2018-2019 IBBS in seven districts/cities of West Java among the injecting drug user population. The study revealed a 9% positivity rate of HIV/HCV co-infection among injecting drug users. Several factors were found to be correlated with HIV/HCV co- infection, including age, gender, education level, marital status, history of imprisonment, age at first drug use through injection, duration of drug injection, use of unsterile equipment, age at first sexual intercourse, sexual activity within the past year, condom usage with regular partners, comprehensive knowledge of HIV, access to sterile syringe services, and access to methadone treatment. These findings emphasize the need for targeted interventions to prevent and address the high incidence of HIV/HCV co-infection within the injecting drug user population. "

"[ABSTRAKLatar belakang. Uji saring darah donor dapat menurunkan risiko tertularnya infeksi HCV. Di Indonesia telah dilakukan uji saring terhadap antibodi HCVdan RNA HCV. Uji saring terhadap Antigen-Antibodi belum dilakukan diIndonesia. Antigen HCV biasanya ditemukan pada 0 sampai 20 hari setelah RNA HCV pertama muncul. Anti-HCV dapat terdeteksi antara 10-40 harisetelah antigen HCV terdeteksi. Atas dasar pemikiran bahwa antigen HCVmuncul didalam darah lebih dahulu daripada anti-HCV, maka penelitian yangdilakukan ingin melihat apakah penggunaan reagensia serologi antigen-antibodi HCV dapat meningkatkan keamanan darah dan apakah sensitivitas serta spesifisitasnya sudah memenuhi standard yang dikeluarkan oleh Kementerian Kesehatan bila dibandingkan terhadap metoda NAT, yaitu sensitivitas 99,8% dan spesifisitas 95%.Metodologi. Pada penelitian ini dilakukan pemeriksaan pada 135 sampel darah donor yang terdiri dari 35 sampel positif dengan NAT HCV dan 100 sampel Positif dengan NAT HCV juga non reaktif terhadap HIV, HBsAg dan Sifilis dengan uji saring anti-HCV dengan metode CMIA, Ab-Ag HCV dengan metode ELISA dan bila ada perbedaan hasil pada pemeriksaan NAT HCV,CMIA HCV dan ELISA Ag-Ab HCV dilakukan pemeriksaan dengan menggunakan imunoblot HCV.Hasil. Dari 135 sampel, pada pemeriksaan ELISA Ag-Ab HCV terhadap 35 sampel positif RNA HCV menunjukkan hasil positif pada 35 sampel tersebut,tetapi pada 100 sampel negatif RNA HCV terdapat 3 sampel reaktif dan 97 nonreaktif. Sedangkan pada 35 sampel positif RNA HCV dengan pemeriksaanCMIA anti-HCV menunjukkan hasil reaktif pada 35 sampel dan pada 100 sampel negatif RNA HCV terdapat 11 sampel reaktif dan 89 sampel non reaktif.Sensitivitas dari perbandingan hasil pemeriksaan metoda NAT HCV dengan CMIA Ab-HCV adalah 100%, spesifisitasnya adalah 89%. Sensitivitas dari perbandingan hasil pemeriksaan metoda NAT HCV dengan ELISA Ag-AbHCV adalah 100%, spesifisitasnya adalah 97%.Simpulan. Pemeriksaan Antigen-Antibodi HCV ELISA memenuhi kriteriastandar untuk digunakan sebagai uji saring darah donor. Pemeriksaan AntibodiHCV CMIA tidak memenuhi kriteria standar untuk digunakan sebagai uji saringdarah donor.

---

ABSTRACTBackground. Screening of donor blood may reduce the risk of transmission of HCV infection . In Indonesia has be screened for HCV antibodies and HCVRNA . Screened against the antigen - antibody has not been done in Indonesia .HCV antigens commonly found in 0 to 20 days after HCV RNA first appears .Anti - HCV can be detected between 10-40 days after HCV antigen wasdetected . On the basis of the notion that HCV antigens appear in the blood earlier than the anti - HCV , the research done to see if the use of antigen - antibody reagents HCV serology can improve blood safety and whether thesensitivity and specificity already meet the standards issued by the Ministry of Health when compared to NAT method , the sensitivity 99.8 % and specificity of 95 % . Methodology. In this study conducted checks on 135 blood samples from 35 donors comprising the NAT HCV positive samples and 100 samples positive by HCV NAT is also non- reactive to HIV , HBsAg and syphilis with anti - HCVscreening of the CMIA method, HCV Ab-Ag ELISA method and theexamination confirmed using immunoblot HCV HCV . Results. Of the 135 samples, the Ag-Ab ELISA against HCV 35 HCV RNA positive samples showed positive results in 35 samples, but at 100 HCV RNA negative samples contained 3 samples reactive and non- reactive 97. While the35 HCV RNA positive samples with anti-HCV CMIA examination showedreactive results on 35 samples and in 100 HCV RNA negative samples contained 11 samples 89 samples reactive and non reactive. Sensitivity of theresults of the comparison method with CMIA HCV NAT-HCV Ab was 100%,specificity was 89%. Sensitivity of the results of the comparison method of NAT HCV Ag-Ab ELISA with HCV was 100%, specificity was 97%. Conclusion. Examination of HCV Antigen-Antibody ELISA meet the standard criteria for use as a screening of donor blood. Examination of HCV antibodiesCMIA does not meet the standard criteria for use as a screening of donor blood.;Background. Screening of donor blood may reduce the risk of transmission of HCV infection . In Indonesia has be screened for HCV antibodies and HCVRNA . Screened against the antigen - antibody has not been done in Indonesia .HCV antigens commonly found in 0 to 20 days after HCV RNA first appears .Anti - HCV can be detected between 10-40 days after HCV antigen wasdetected . On the basis of the notion that HCV antigens appear in the blood earlier than the anti - HCV , the research done to see if the use of antigen - antibody reagents HCV serology can improve blood safety and whether thesensitivity and specificity already meet the standards issued by the Ministry of Health when compared to NAT method , the sensitivity 99.8 % and specificity of 95 % . Methodology. In this study conducted checks on 135 blood samples from 35 donors comprising the NAT HCV positive samples and 100 samples positive by HCV NAT is also non- reactive to HIV , HBsAg and syphilis with anti - HCVscreening of the CMIA method, HCV Ab-Ag ELISA method and theexamination confirmed using immunoblot HCV HCV . Results. Of the 135 samples, the Ag-Ab ELISA against HCV 35 HCV RNA positive samples showed positive results in 35 samples, but at 100 HCV RNA negative samples contained 3 samples reactive and non- reactive 97. While the35 HCV RNA positive samples with anti-HCV CMIA examination showedreactive results on 35 samples and in 100 HCV RNA negative samples contained 11 samples 89 samples reactive and non reactive. Sensitivity of theresults of the comparison method with CMIA HCV NAT-HCV Ab was 100%,specificity was 89%. Sensitivity of the results of the comparison method of NAT HCV Ag-Ab ELISA with HCV was 100%, specificity was 97%. Conclusion. Examination of HCV Antigen-Antibody ELISA meet the standard criteria for use as a screening of donor blood. Examination of HCV antibodiesCMIA does not meet the standard criteria for use as a screening of donor blood., Background. Screening of donor blood may reduce the risk of transmission of HCV infection . In Indonesia has be screened for HCV antibodies and HCVRNA . Screened against the antigen - antibody has not been done in Indonesia .HCV antigens commonly found in 0 to 20 days after HCV RNA first appears .Anti - HCV can be detected between 10-40 days after HCV antigen wasdetected . On the basis of the notion that HCV antigens appear in the blood earlier than the anti - HCV , the research done to see if the use of antigen - antibody reagents HCV serology can improve blood safety and whether thesensitivity and specificity already meet the standards issued by the Ministry of Health when compared to NAT method , the sensitivity 99.8 % and specificity of 95 % . Methodology. In this study conducted checks on 135 blood samples from 35 donors comprising the NAT HCV positive samples and 100 samples positive by HCV NAT is also non- reactive to HIV , HBsAg and syphilis with anti - HCVscreening of the CMIA method, HCV Ab-Ag ELISA method and theexamination confirmed using immunoblot HCV HCV . Results. Of the 135 samples, the Ag-Ab ELISA against HCV 35 HCV RNA positive samples showed positive results in 35 samples, but at 100 HCV RNA negative samples contained 3 samples reactive and non- reactive 97. While the35 HCV RNA positive samples with anti-HCV CMIA examination showedreactive results on 35 samples and in 100 HCV RNA negative samples contained 11 samples 89 samples reactive and non reactive. Sensitivity of theresults of the comparison method with CMIA HCV NAT-HCV Ab was 100%,specificity was 89%. Sensitivity of the results of the comparison method of NAT HCV Ag-Ab ELISA with HCV was 100%, specificity was 97%. Conclusion. Examination of HCV Antigen-Antibody ELISA meet the standard criteria for use as a screening of donor blood. Examination of HCV antibodiesCMIA does not meet the standard criteria for use as a screening of donor blood.]"

"Currently, we reported results of a nested polymerase chain reaction (PCR) assay specific 5` untranslated region (UTR)region of hepatitis C virus (HCV) genome that showed three different patterns of deoxyribonucleic acid (DNA)fragments (single expected specific DNA band, single DNA band higher in size than an expected band, and multipleDNA bands). Three isolates (Isolate A, B, and C), representing all the three DNA bands, were analyzed by usingphylogenetic trees. The results showed that the Isolate A, B, and C were classified into HCV genotypes 2, 1, and 3,respectively. The Isolate A and B were very closely related to viral isolates from Madagascar and Brazil, respectivelyand were not closely related to other Indonesia isolates. In contrast with the Isolate A and B, the Isolate C was veryclosely related to another Indonesia isolate. Among all there isolates, the Isolate C was very closely related to anIndonesia isolate detected from a cirrhosis patient, indicating that the Isolate C might be more virulence than the IsolateB and C. However, a complete genome-based comprehensive genetic characterization for all the three isolates needs tobe conducted in future research to confirm all findings in this study.Analisis Filogenetik Berbasis Region5` yang Tidak Ditranslasikan Sebagian (Partly 5` UTR) terhadap Tiga IsolatVirus Hepatitis C di Jakarta, Indonesia: Kajian Pendahuluan. Makalah ini adalah laporan hasil pengujian genomHCV dengan metode nested PCR 5` UTR spesifik yang menunjukkan adanya tiga pola fragmen DNA yang berbeda(untai DNA spesifik yang diekspektasi tunggal, untai DNA tunggal yang berukuran lebih tinggi daripada untai yangdiekspektasi, dan untai DNA majemuk). Tiga isolat (Isolat A, B, dan C) yang mewakili tiga berkas DNA itu dianalisisdengan pohon filogenetik. Hasil penelitian menunjukkan bahwa Isolat A, B, dan C tergolong genotipe HCV 2, 1, dan 3secara berturut-turut. Isolat A dan B masing-masing berhubungan erat dengan isolat virus dari Madagaskar dan Brazil,meskipun keduanya tidak berhubungan erat dengan isolat dari Indonesia. Berbeda dengan isolat A dan B, Isolat Cberhubungan erat dengan isolat dari Indonesia. Di antara ketiga isolat, Isolat C memiliki hubungan paling erat denganisolat Indonesia yang ditemukan pada seorang pasien kirosis. Hal ini menunjukkan adanya kemungkinan bahwa Isolat Clebih berbahaya daripada Isolat B dan C. Bagaimanapun, karakterisasi genetis komprehensif berbasis genom yanglengkap terhadap ketiga isolat perlu dilaksanakan pada kajian-kajian berikutnya untuk mendukung hasil penelitian ini."

"Currently, we reported results of a nested polymerase chain reaction (PCR) assay specific 5` untranslated region (UTR) region of hepatitis C virus (HCV) genome that showed three different patterns of deoxyribonucleic acid (DNA) fragments (single expected specific DNA band, single DNA band higher in size than an expected band, and multiple DNA bands). Three isolates (Isolate A, B, and C), representing all the three DNA bands, were analyzed by using phylogenetic trees. The results showed that the Isolate A, B, and C were classified into HCV genotypes 2, 1, and 3, respectively. The Isolate A and B were very closely related to viral isolates from Madagascar and Brazil, respectively and were not closely related to other Indonesia isolates. In contrast with the Isolate A and B, the Isolate C was very closely related to another Indonesia isolate. Among all there isolates, the Isolate C was very closely related to an Indonesia isolate detected from a cirrhosis patient, indicating that the Isolate C might be more virulence than the Isolate B and C. However, a complete genome-based comprehensive genetic characterization for all the three isolates needs to be conducted in future research to confirm all findings in this study."

"ABSTRAKAnti-HCV menjadi marker serologi utama yang digunakan untuk uji saring hepatitis C pada donor darah di Indonesia. Selain serologi anti-HCV, untuk lebih meningkatkan kemananan darah, Unit Transfusi Darah UTD DKI Jakarta juga menerapkan pemeriksaan Nucleic Acid Test NAT . Pemeriksaan anti-HCV tidak dapat membedakan antara infeksi aktif dan infeksi yang telah sembuh. Darah akan dianggap terifeksi HCV apabila salah satu dari pemeriksaan serologi atau molekuler positif, begitupula dengan darah donor dengan hasil pemeriksaan anti-HCV grayzone dan NAT negatif. Diperlukan kepastian atas berisiko tidaknya darah tersebut dalam menularkan infeksi HCV, mengingat kebutuhan darah di sebagian besar provinsi di Indonesia masih belum memenuhi target. Sehingga dibutuhkan uji molekuler lain untuk dijadikan pembanding dengan hasil NAT. Interpretasi hasil anti-HCV dilakukan berdasarkan rasio S/CO, yang dapat dijadikan prediksi status viremia donor, sehingga perlu dilakukan analisis hubungan antara S/CO dengan hasil pengujian molekuler dan HCV Ag-Ab. Nilai prediksi viremia diharapkan dapat menjadi alternatif bagi UTD yang belum mampu menerapkan NAT. Kemudian dipilih 93 sampel dengan kriteria anti-HCV positif dan NAT positif; anti-HCV positif dan NAT negatif serta anti-HCV grayzone dan NAT negatif untuk diuji dengan nested PCR kualitatif dan HCV Ag-Ab. Berdasarkan perbandingan hasil pengujian NAT dan nested PCR diperoleh nilai sensitivitas NAT sebesar 90, 63 , dengan Spesifisitasnya 96,71 . Dari hasil analisis chi-square diperoleh hubungan yang bermakna antara nilai S/CO anti-HCV dengan hasil pengujian NAT, nested PCR kualitatif dan HCV Ag-Ab P5 dapat dijadikan prediksi adanya infeksi aktif pada donor.

---

ABSTRACTAnti HCV is the main serological marker for hepatitis C screening in blood donors in Indonesia. Besides anti HCV, UTD DKI Jakarta also implementing Nucleic Acid Test NAT to improve blood transfusion safety. Anti HCV assay can not distinguish between active infection and cured infection. Blood will be considered HCV infected if either from a positive serologic or molecular test, including blood with anti HCV grayzone and NAT negative. There is a requirement to ensure the risk status of blood with anti HCV grayzone and NAT negative, because the supply of blood in most provinces in Indonesia still insufficient. So, it takes another molecular test to compare with NAT result. Interpretation of anti HCV results was calculating by S CO ratio, which could be a predictor of viremia status. It is necessary to analyze the correlation between S CO with molecular test and HCV Ag Ab results.Viremia prediction value is expected to be an alternative for UTDs who have not been able to apply NAT. There are 93 samples collected then tested with NAT and anti HCV. Sample with concondantly positive anti HCV and NAT anti HCV positive and NAT negative and anti HCV grayzone and NAT negative. These samples then tested with nested PCR and HCV Ag Ab. Based on comparison of NAT and nested PCR, obtained NAT sensitivity value of 90, 63 , with Specificity 96.71 . The result of chi square analysis shows a significant correlation between S CO anti HCV with NAT, qualitative nested PCR and HCV Ag Ab P 5 can be used as predictors of active infection in donors. "

"ABSTRAKHepatitis C virus HCV menginfeksi lebih dari 170 juta penduduk dunia dan menyebabkan penyakit hati kronis yang berkembang menjadi sirosis dan kanker hati. Diagnosis yang akurat sangat diperlukan untuk memberikan penanganan tepat secara dini, termasuk mencegah penularan virus tersebut secara lebih luas. Pada penelitian ini plasmid pQE80L-HCV_ME telah berhasil dibuat untuk produksi antigen rekombinan HCV. Gen pengkode antigen tersebut dirancang berdasarkan multiepitop yang bersifat imunodominan, lestari, mewakili subtipe HCV di Indonesia dan global. Gen tersebut dibuat dengan teknik DNA sintetik kemudian diklona dari plasmid pUC57 ke pQE80L. Pengklonaan dilakukan menggunakan situs restriksi BamHI dan HindIII dalam sel E. coli Top10. Plasmid pQE80L-HCV_ME kemudian diverifikasi dengan PCR koloni, analisis restriksi, dan sekuensing.

---

ABSTRACTHepatitis C virus HCV have been infected more than 170 million people in the world and caused chronic liver disease that lead to liver cirrhosis and hepatocellular carcinoma. Accurate diagnosis is very important to give early proper treatment and to prevent HCV transmission broadly. In this research pQE80L HCV ME plasmid has been successfully created to produce HCV recombinant antigen. Gene that encodes antigen was designed based on multiepitop sequences from immunodominat region, conserve, and represent the most prevalence HCV subtypes in Indonesia and global. The gene was generated through synthetic DNA then be cloned from pUC57 plasmid to pQE80L. Cloning was performed by using BamHI dan HindIII in E. coli Top10 cell. pQE80L HCV ME plasmid then be verified by colonies PCR, restriction analysis, and sequencing."

"Hepatitis C Virus (HCV) adalah virus yang menginfeksi hati dan menyebabkan penyakit serius dalam jangka panjang. Pengobatan saat ini menggunakan obat Direct-Acting Antiviral (DAA), namun adanya variasi genotipe dan resistensi terkait mutasi dapat menyebabkan kegagalan pengobatan, sehingga memerlukan pengembangan kandidat antivirus baru. Ekstrak daun P. betle telah dilaporkan memiliki aktivitas anti HCV. Penelitian ini bertujuan untuk mengetahui mekanisme efek antiviral ekstrak daun P. betle terhadap HCV dan potensinya sebagai komplementer dengan telaprevir atau sofosbuvir. Aktivitas antivirus diuji menggunakan sel Huh7it-1 dan HCV genotipe 2a (JFH1a), kemudian dianalisis persentase penghambatan dengan titrasi pada kultur sel dan qRT-PCR. Efek sinergis dan antagonis dengan telaprevir atau sofosbuvir dianalisis dengan perangkat lunak CompuSyn. Analisis in silico juga dilakukan untuk memprediksi interaksi senyawa pada ekstrak daun P. betle dengan protein NS3, NS5A, dan NS5B. Ekstrak daun P. betle diketahui mampu menghambat replikasi HCV, dengan daya hambat pada semua perlakuan lebih rendah dibandingkan kontrol. Kombinasi dengan telaprevir menunjukkan efek antagonis, sedangkan kombinasi dengan sofosbuvir menunjukkan efek sinergis pada konsentrasi tinggi, tanpa menyebabkan toksisitas. Prediksi interaksi mengidentifikasi senyawa ‐fenilpropena‐3,3‐diol diasetat dan 4-Allyl-1,2-diasetoksibenzena memiliki interaksi kuat dengan protein NS5A dan NS5B. Energi ikat masing-masingnya -6,86 kkal/mol dan -6,40 kkal/mol pada NS5A, serta 6,01 kkal/mol dan -5.93 kkal/mol pada NS5B. Dari penelitian ini dapat disimpulkan bahwa, ekstrak daun P. betle mampu menghambat replikasi HCV dan memiliki potensi sebagai komplementer dengan sofosbuvir pada konsentrasi tinggi.

---

Hepatitis C Virus (HCV) is a virus that infects the liver and causes serious disease in the long term. Current treatment uses Direct-acting Antiviral (DAA) drugs, but the presence of genotypic variations and resistance-associated mutations cause treatment failure, thus requiring the development of new antiviral candidates. P. betle leaf extract has anti-HCV activity. This study analyzes the antiviral mechanism and its potential synergy with telaprevir or sofosbuvir. Antiviral activity was tested using Huh7it-1 cells and HCV genotype 2a (JFH1a), then the inhibitory activity was analyzed by titration on cell culture and qRT-PCR. Synergistic and antagonistic effects with telaprevir or sofosbuvir were analyzed with CompuSyn software. In silico analysis was also carried out to predict the interaction of compounds in P. betle leaf extract with NS3, NS5A, and NS5B proteins. P. betle leaf extract is known to be able to inhibit HCV replication, with virus inhibition in all treatments being lower than the control. The combination with telaprevir showed an antagonistic effect, while the combination with sofosbuvir showed a synergistic effect at high concentration without causing toxicity. Interaction prediction identified the compounds 1-phenylpropene-3,3-diol diacetate and 4-allyl-1,2- diacetoxybenzene as having strong interactions with the NS5A and NS5B proteins, with binding energies of -6.86 kcal/mol and -6 .40 kcal/mol in NS5A, and 6.01 kcal/mol and -5.93 kcal/mol in NS5B, respectively. Based on this research, we conclude that P. betle leaf extract can inhibit HCV replication and has the potential to act as a complement to sofosbuvir at high concentrations."